Efficacy of non-ablative fractional 1440-nm laser therapy for treatment of facial acne scars in patients with rosacea: a prospective, interventional study.

Lasers Med Sci

Department of Dermatology, Xiangya Hospital, Central South University, Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China.

Published: April 2021

Acne scarring is one of the most common facial skin disorders. The appropriate treatments for acne scars in patients with rosacea have not been studied. This study was designed to evaluate the efficacy and safety of non-ablative fractional 1440-nm laser (1440-nm NAFL) therapy for treatment of atrophic acne scars in patients with rosacea. In this prospective, interventional study, 32 patients with rosacea and acne scars underwent three sessions of 1440-nm NAFL therapy. Therapy efficacy, epidermal barrier function, and side effects were evaluated. Thirty patients completed and the median acne scar scores significantly reduced from 45 (30, 50) to 15 (15, 30) after three treatments (P < 0.001). The improvement score of acne scars was 2.7 ± 0.7; 22 (73.3%) were satisfied or highly satisfied. The rosacea erythema scores changed from 2.1 ± 0.4 to 1.9 ± 0.5 (P = 0.326), and flushing, burning, and stinging were not worse. The oil content after treatments was significantly reduced (P < 0.001), while there was no significant difference in other indicators of skin barrier function. The quality-of-life score decreased from 17.5 ± 3.8 to 14.1 ± 3.0 (P < 0.001). No serious side effects were observed. The 1440-nm NAFL therapy is effective in the treatment of acne scaring in patients with rosacea with little damage to the skin barrier.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10103-020-03107-xDOI Listing

Publication Analysis

Top Keywords

acne scars
16
patients rosacea
16
scars patients
12
non-ablative fractional
8
fractional 1440-nm
8
1440-nm laser
8
therapy treatment
8
rosacea prospective
8
prospective interventional
8
interventional study
8

Similar Publications

Introduction: Acne impairs quality of life, often leads to permanent scars, and causes psychological distress. This review aims to update dermatologists on the Federal Drug Administration (FDA)-approved and off-label use of combined oral contraceptives (COC), clascoterone, spironolactone, and emerging hormonal therapies for acne treatment.

Methods: We reviewed current literature on hormonal acne treatments and discussed common patient concerns, barriers to care, and individualized care needs.

View Article and Find Full Text PDF

Bridging the Gap in Acne Vulgaris Research for Skin of Color Patients.

J Am Acad Dermatol

December 2024

Department of Dermatology, Weill Cornell Medicine, New York, NY, USA. Electronic address:

View Article and Find Full Text PDF

Acne vulgaris (AV) is a common dermatological condition that ranges from mild comedones to severe inflammatory nodules and scarring. Effective management is essential for improving patients' quality of life. The recent FDA approval of IDP-126 (Cabtreo™), a novel triple-combination gel, meets these needs by combining clindamycin phosphate, benzoyl peroxide, and adapalene into a single formulation.

View Article and Find Full Text PDF

Background: Acne is a common inflammatory dermatosis. Although gender-related differences in prevalence and age of onset have been documented. Other gender-related characteristics of acne have not been well elucidated yet.

View Article and Find Full Text PDF

Dissecting cellulitis (DC) of the scalp is a chronic inflammatory condition marked by neutrophilic cicatricial alopecia, often linked to staphylococcal antigens. This case report details a 34-year-old male with scarring acne who developed DC following follicular unit extraction (FUE) approximately four months prior. Trichoscopic examination revealed brown pigmented dots, erythema, and melicerous crusts.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!